Pancreatic
RASolute 303 (RMC-6236-303)
A Phase 3 Multicenter, Open-label, Randomized, 3-Arm Study of Daraxonrasib Monotherapy or Daraxonrasib Plus Gemcitabine and Nab-paclitaxel Q2W versus Gemcitabine and Nab-paclitaxel as a First-Line Treatment for Patients with Metastatic Pancreatic Ductal Adenocarcinoma (PDAC).
Trial overview
Clinical Area
Medical Oncology
Disease
Pancreatic
Disease site
Gastrointestinal (GI)
Study Phase
III
Trial Identifiers
Registration number: NCT07491445
Principal Investigator(s)
··
··